

# Detection of pseudoprogression using CT perfusion in patients with Glioblastoma Multiforme post-treatment

<b>Submission date</b> 20/04/2015	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 01/07/2015	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 06/06/2018	<b>Condition category</b> Cancer	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

<http://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-study-using-a-ct-scan-to-detect-false-growth-in-brain-tumours-after-treatment-ctpip>

## Contact information

### Type(s)

Scientific

### Contact name

Dr Kumar Das

### Contact details

Radiology Department  
The Walton Centre NHS Foundation Trust  
Fazakerley  
Liverpool  
United Kingdom  
L9 7LJ  
+44 (0)151 529 5538  
[kumar.das@thewaltoncentre.nhs.uk](mailto:kumar.das@thewaltoncentre.nhs.uk)

## Additional identifiers

### Protocol serial number

N/A

## Study information

## **Scientific Title**

Detection of pseudoprogression using CT perfusion in patients with Glioblastoma Multiforme post-treatment: an observational cohort study

## **Study objectives**

This study will use CT perfusion scans to look for changes in the brain following treatment for a brain tumour. It is often difficult to detect changes in the brain that are caused as a result of the treatment effects, for example residual damage following radiosurgery may initially look like the tumour has progressed. Using CT perfusion techniques, additional physiological information relating to the tumour site can be acquired which will assist in the correct treatment management of the patient. It should be noted however that patients do not at present have a CT perfusion examination to assist in monitoring the progress of their tumour surveillance over their course of the patient's treatment, therefore this study would require additional ionising radiation, as the patients are only monitored using MRI perfusion techniques at this time.

## **Ethics approval required**

Old ethics approval format

## **Ethics approval(s)**

North West - Haydock Research Ethics Committee, 01/06/2015, ref: 15/NW/0399

## **Study design**

Prospective observational cohort study

## **Primary study design**

Observational

## **Study type(s)**

Diagnostic

## **Health condition(s) or problem(s) studied**

Glioblastoma Multiforme

## **Interventions**

A single CT perfusion scan will be carried out during the study. The study will be prospective and each patient will follow the procedure below:

Newly diagnosed patients with glioblastoma multiforme tumour will be given a neurosurgical referral, and then offered a course of treatment, depending on the classification of the tumour that will be either, or a combination of chemotherapy, radiosurgery or neurosurgery. After 3 months of treatment, the patient will undergo post-operative MRI. If the MRI scan shows no progression, the normal protocols will be followed. If the MRI scan shows tumour progression, they will have their case discussed at a multi-disciplinary team meeting (comprising neurosurgeons, neurologists, neuroradiologists and oncology nursing staff). If there is clinical progression (symptoms are reported to be present or worsening) present, an MRI perfusion scan will be performed and the clinical team will decide on further treatment management, which could include more surgery, radiotherapy or chemotherapy. If no clinical progression has been identified, the patient will undergo CT perfusion and MR perfusion on the same day, and be discharged. The CT and MRI perfusion scans will be reviewed and used for further management /monitoring. At 8 weeks post-treatment, if there is no clinical progression and no tumour progression on the scans, pseudoprogression of the tumour is likely. If after 8 weeks, there has been clinical symptom progression and this is seen on the scans, the patient will be followed up

8 weeks later. Incidence rate and frequency will be calculated using Two-tailed student t-test and ROC curve for analysis of sensitivity and specificity. Potential benefits include the timely and more accurate detection of pseudoprogression in this patient group, allowing changes relating to their treatment to be tailored accordingly. The sensitivity and specificity of CT perfusion in the differentiation between true tumour progression and pseudoprogression.

**Intervention Type**

Procedure/Surgery

**Primary outcome(s)**

Diagnosis of true tumour progression measured by MRI scan 8 weeks after treatment

**Key secondary outcome(s)**

Better diagnosis and improved treatment options

**Completion date**

01/03/2016

## Eligibility

**Key inclusion criteria**

1. Patients with glioblastoma multiforme tumours who will be discussed in the regional neuro-oncology multidisciplinary team meeting
2. Patients exhibiting any tumour progression on their first follow-up imaging immediately after radiotherapy, surgery or chemotherapy post-treatment without clinical progression

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

All

**Key exclusion criteria**

Patients who exhibit tumour progression both clinically (symptoms) and on imaging on the first follow-up imaging immediately following radiotherapy, chemotherapy or surgery following treatment

**Date of first enrolment**

01/05/2015

**Date of final enrolment**

01/05/2016

## Locations

## Countries of recruitment

United Kingdom

England

## Study participating centre

The Walton Centre NHS Foundation Trust

Lower Lane

Fazakerley

Liverpool

United Kingdom

L9 7LJ

## Sponsor information

### Organisation

The Walton Centre NHS Foundation Trust

### ROR

<https://ror.org/05cvxat96>

## Funder(s)

### Funder type

Government

### Funder Name

The Walton Centre NHS Foundation Trust (UK)

## Results and Publications

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Available on request

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
-------------	---------	--------------	------------	----------------	-----------------

<a href="#">HRA research summary</a>		28/06/2023	No	No
<a href="#">Participant information sheet</a>	version V1.2	09/05/2016	No	Yes